α-[ 11C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: Clinical studies

Biomarkers in Medicine

Volumn 5, Issue 5, 2011, Pages 577-584

  Kumar, Ajay ^a,b   Asano, Eishi ^a,b   Chugani, Harry T ^a,b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

methyl tryptophan; cortical dysplasia; developmental cortical malformations; epilepsy; PET; tuberous sclerosis

Indexed keywords

N METHYLTRYPTOPHAN C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ALPHA-METHYLTRYPTOPHAN; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; N METHYLTRYPTOPHAN; TRYPTOPHAN;

BRAIN MALFORMATION; BRAIN REGION; CLINICAL STUDY; CORTICAL DEVELOPMENTAL MALFORMATION; CORTICAL DYSPLASIA; DRUG HALF LIFE; EPILEPSY; HUMAN; NEUROSURGERY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TUBEROUS SCLEROSIS; BRAIN; CHEMISTRY; METABOLISM; SCINTISCANNING;

BIOLOGICAL MARKERS; BRAIN; EPILEPSY; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TRYPTOPHAN; TUBEROUS SCLEROSIS;

EID: 80054811727     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.68     Document Type: Review

References (33)

1. Arroyo S. [Evaluation of drug-resistant epilepsy] [Article in Spanish]. Rev. Neurol. 30(9), 881-886 (2000). (Pubitemid 30436302)
2. Guerrini R, Sicca F, Parmeggiani L. Epilepsy and malformations of the cerebral cortex. Epileptic Disord. 5(Suppl. 2), S9-S26 (2003). (Pubitemid 37238274)
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342(5), 314-319 (2000). (Pubitemid 30075244)
4. Obeid M, Wyllie E, Rahi AC, Mikati MA. Approach to pediatric epilepsy surgery: state of the art, Part I: General principles and presurgical workup. Eur. J. Paediatr. Neurol. 13(2), 102-114 (2009).
5. Juhász C, Chugani DC, Muzik O, et al. α-methyl-l-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy. Neurology 60(6), 960-968 (2003). (Pubitemid 36348928)
6. Wakamoto H, Chugani DC, Juhász C, Muzik O, Kupsky WJ, Chugani HT. α-methyl-l-tryptophan positron emission tomography in epilepsy with cortical developmental malformations. Pediatr. Neurol. 39(3), 181-188 (2008).
7. Chugani DC. α-methyl-l-tryptophan: mechanisms for tracer localization of epileptogenic brain regions. Biomarkers Med. 5(5), 567-575 (2011).
8. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51(7), 1236-1241 (2010).
9. Jozwiak S, Schwartz RA, Janniger CK, Bielickα-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J. Child Neurol. 15(10), 652-659 (2000).
10. Crino PB. Molecular pathogenesis of tuber formation in tuberous sclerosis complex. J. Child Neurol. 19(9), 716-725 (2004). (Pubitemid 39530082)
11. Uhlmann EJ, Wong M, Baldwin RL, et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 52(3), 285-296 (2002). (Pubitemid 35001494)
12. Jansen FE, Van Huffelen AC, Algra A, Van Nieuwenhuizen O. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia 48(8), 1477-1484 (2007). (Pubitemid 47245804)
13. Kagawa K, Chugani DC, Asano E, et al. Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with α-[11C]-methyl-l- tryptophan positron emission tomography (PET). J. Child Neurol. 20(5), 429-438 (2005). (Pubitemid 40873049)
14. Teutonico F, Mai R, Devinsky O, et al. Epilepsy surgery in tuberous sclerosis complex: early predictive elements and outcome. Childs Nerv. Syst. 24(12), 1437-1445 (2008).
15. Weiner HL, Carlson C, Ridgway EB, et al. Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics 117(5), 1494-1502 (2006). (Pubitemid 46071375)
16. Wu JY, Salamon N, Kirsch HE, et al. Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex. Neurology 74(5), 392-398 (2010).
17. Rintahaka PJ, Chugani HT. Clinical role of positron emission tomography in children with tuberous sclerosis complex. J. Child Neurol. 12(1), 42-52 (1997). (Pubitemid 27043837)
18. Szelies B, Herholz K, Heiss WD, et al. Hypometabolic cortical lesions in tuberous sclerosis with epilepsy: demonstration by positron emission tomography. J. Comput. Assist. Tomogr. 7(6), 946-953 (1983). (Pubitemid 14246630)
19. Koh S, Jayakar P, Resnick T, Alvarez L, Liit RE, Duchowny M. The localizing value of ictal SPECT in children with tuberous sclerosis complex and refractory partial epilepsy. Epileptic Disord. 1(1), 41-46 (1999).
20. Asano E, Chugani DC, Muzik O, et al. Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex. Neurology 54(10), 1976-1984 (2000). (Pubitemid 30327123)
21. Chugani DC, Chugani HT, Muzik O, et al. Imaging epileptogenic tubers in children with tuberous sclerosis complex using α-[11C]methyl-l-tryptophan positron emission tomography. Ann. Neurol. 44(6), 858-866 (1998). (Pubitemid 28558246)
22. Fedi M, Reutens DC, Andermann F, et al. α-[11C]-methyl-l-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Res. 52(3), 203-213 (2003). (Pubitemid 36106565)
23. Asano E, Chugani DC, Muzik O, et al. Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology 57(7), 1269-1277 (2001). (Pubitemid 32947387)
24. Eluvathingal TJ, Behen ME, Chugani HT, et al. Cerebellar lesions in tuberous sclerosis complex: neurobehavioral and neuroimaging correlates. J. Child Neurol. 21(10), 846-851 (2006). (Pubitemid 46099270)
25. Fedi M, Reutens D, Okazawa H, et al. Localizing value of α-methyl-l-tryptophan PET in intractable epilepsy of neocortical origin. Neurology 57(9), 1629-1636 (2001). (Pubitemid 33055481)
26. Sisodiya SM. Surgery for malformations of cortical development causing epilepsy. Brain 123(Pt 6), 1075-1091 (2000). (Pubitemid 30312101)
27. Wyllie E, Comair YG, Kotagal P, Bulacio J, Bingaman W, Ruggieri P. Seizure outcome after epilepsy surgery in children and adolescents. Ann. Neurol. 44(5), 740-748 (1998). (Pubitemid 28516044)
28. Bingaman WE, Cataltepe O. Epilepsy surgery for focal malformation of cortical development. In:Epilepsy Surgery . Luders HO, Comair YG (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001).
29. Natsume J, Bernasconi N, Aghakhani Y, et al. α-[11C]methyl-l- tryptophan uptake in patients with periventricular nodular heterotopia and epilepsy. Epilepsia 49(5), 826-831 (2008). (Pubitemid 351652441)
30. Chugani HT, Kumar A, Kupsky W, Asano E, Sood S, Juhász C. Clinical and histopathologic correlates of 11C-α-methyl-l-tryptophan (AMT) PET abnormalities in children with intractable epilepsy. Epilepsia 52(9), 1692-1698 (2011).
31. Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental and genetic classification for malformations of cortical development. Neurology 65(12), 1873-1887 (2005). (Pubitemid 43970104)
32. Juhász C, Chugani DC, Padhye UN, et al. Evaluation with α-[11C]methyl-l-tryptophan positron emission tomography for reoperation after failed epilepsy surgery. Epilepsia 45(2), 124-130 (2004). (Pubitemid 38174118)
33. Chugani HT, Juhász C, Chugani DC, et al. Increased striatal serotonin synthesis following cortical resection in children with intractable epilepsy. Epilepsy Res. 78(2-3), 124-130 (2008).